ReviewInternational journal of molecular sciences2026
Peripheral GABA Signaling in Metabolic Adaptation and Maladaptation.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Peripheral γ-aminobutyric acid (GABA) signaling is emerging as a context-dependent contributor to metabolic regulation. Long recognized as the principal inhibitory neurotransmitter in the central nervous system, GABA's role as an important signal in peripheral tissues is recently getting attention. This expanded view raises a central question: why do GABA-sensitive pathways support regulation in some metabolic settings, yet reinforce dysfunction in others? In obesity and type 2 diabetes mellitus (T2DM), nutrient excess, insulin resistance, and chronic inflammation remodel the cellular environments in which GABA is produced, sensed, and metabolized. As a result, GABA signaling may shift from adaptive regulation that maintains tissue function to compensatory responses that attempt to limit metabolic stress, and ultimately to maladaptive outputs that reinforce disease progression. Here, we review the biochemical basis, sources, receptor systems, and extracellular regulation of peripheral GABA signaling. We then examine how GABA-sensitive pathways are organized across metabolic tissues and remodeled in obesity and T2DM, with emphasis on islet endocrine dysfunction, hepatic GABA output, and adipose-immune-microbiota interactions. We further consider how this framework informs pathway-specific therapeutic strategies and the barriers to translation. We propose that peripheral GABA signaling is neither inherently protective nor harmful. Its metabolic consequence depends on the source of GABA, the responding tissue environment, and the stage of metabolic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.